For patients with leukemia, platelets can be a feasible prognostic marker for defining both treatment-free and overall survival, according to a study published in the Journal of Medical Biochemistry. Researchers compared mean...
In a recent PW podcast episode, Ryan W. Jacobs, MD, talked about a new real-world study looking at treatment with one of the two approved BTK inhibitors, acalabrutinib and ibrutinib, for chronic lymphocytic leukemia (CLL) In the...